US Stock MarketDetailed Quotes

IOVA Iovance Biotherapeutics

Watchlist
  • 3.540
  • 0.0000.00%
Close Mar 21 16:00 ET
  • 3.540
  • 0.0000.00%
Post 19:55 ET
1.16BMarket Cap-2.77P/E (TTM)

Iovance Biotherapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(FY)Dec 31, 2024
(Q4)Dec 31, 2024
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities
2.44%-352.98M
12.71%-73.3M
29.86%-58.97M
-4.77%-98.43M
-22.51%-122.28M
-23.59%-361.82M
-8.11%-83.97M
-32.10%-84.08M
-21.02%-93.95M
-35.25%-99.82M
Net income from continuing operations
16.18%-372.18M
32.50%-78.56M
26.56%-83.54M
8.85%-97.1M
-5.22%-112.98M
-12.16%-444.04M
-10.50%-116.38M
-14.20%-113.76M
-7.23%-106.53M
-17.21%-107.37M
Operating gains losses
-8,304.29%-5.74M
-5,149.06%-5.56M
-126.05%-93K
--10K
---96K
--70K
---106K
--357K
----
----
Depreciation and amortization
31.63%43.61M
20.31%11.69M
12.89%11.15M
38.55%10.86M
73.90%9.91M
56.74%33.13M
70.21%9.71M
89.83%9.88M
49.41%7.84M
14.44%5.7M
Deferred tax
18.71%-2.83M
188.63%1.56M
-22.37%-1.52M
-205.66%-1.46M
---1.41M
---3.48M
---1.76M
---1.24M
---477K
--0
Change In working capital
-1,779.40%-122.56M
-419.47%-37.98M
-326.10%-13.32M
-237.50%-38.71M
-153.71%-32.55M
-125.48%-6.52M
295.87%11.89M
-45.73%5.89M
-77.66%-11.47M
-24.64%-12.83M
-Change in receivables
-46,335.57%-69.19M
-9,008.72%-13.57M
-73,324.24%-24.16M
-94,960.61%-31.37M
---83K
---149K
---149K
--33K
---33K
--0
-Change in inventory
-294.51%-39.92M
-1,357.20%-13.45M
-3,171.47%-10.87M
7.23%-8.86M
---6.74M
---10.12M
---923K
--354K
---9.55M
--0
-Change in prepaid assets
79.00%-2.11M
-3.30%-5.32M
-214.92%-2.47M
92.55%-211K
239.16%5.89M
-372.39%-10.06M
-280.89%-5.15M
192.92%2.15M
-368.88%-2.83M
-13.89%-4.23M
-Change in payables and accrued expense
-97.00%737K
-109.54%-1.99M
340.18%27.14M
21.44%4.42M
-378.19%-28.83M
1,984.92%24.6M
744.95%20.83M
-55.02%6.17M
147.11%3.64M
17.05%-6.03M
-Change in other current liabilities
-11.86%-12.07M
-34.23%-3.65M
-4.69%-2.95M
0.11%-2.69M
-8.56%-2.79M
-455.82%-10.79M
-17.85%-2.72M
-424.81%-2.81M
-1,369.81%-2.69M
-472.32%-2.57M
Cash from discontinued investing activities
Operating cash flow
2.44%-352.98M
12.71%-73.3M
29.86%-58.97M
-4.77%-98.43M
-22.51%-122.28M
-23.59%-361.82M
-8.11%-83.97M
-32.10%-84.08M
-21.02%-93.95M
-35.25%-99.82M
Investing cash flow
Cash flow from continuing investing activities
37.90%-96.41M
132.50%23.68M
38.24%-48.8M
125.65%40.22M
-172.69%-111.51M
-160.53%-155.24M
-15,901.52%-72.85M
-207.19%-79.01M
-263.72%-156.78M
77.30%153.4M
Net PPE purchase and sale
50.34%-11.07M
-18.11%-4.17M
36.04%-2.29M
95.36%-442K
26.36%-4.17M
-9.13%-22.29M
-16.78%-3.53M
-157.89%-3.58M
-108.04%-9.52M
50.49%-5.66M
Net business purchase and sale
75.28%-52.57M
--0
--0
--0
---52.57M
---212.63M
--253K
---3.38M
---209.51M
--0
Net investment purchase and sale
-141.13%-32.77M
140.03%27.85M
35.45%-46.51M
-34.68%40.66M
-134.43%-54.76M
-71.22%79.68M
-2,097.39%-69.57M
-195.95%-72.06M
-37.96%62.25M
62.38%159.06M
Cash from discontinued investing activities
Investing cash flow
37.90%-96.41M
132.50%23.68M
38.24%-48.8M
125.65%40.22M
-172.69%-111.51M
-160.53%-155.24M
-15,901.52%-72.85M
-207.19%-79.01M
-263.72%-156.78M
77.30%153.4M
Financing cash flow
Cash flow from continuing financing activities
-15.62%390.66M
140.02%2.31M
-79.31%41.95M
14,809.76%152.83M
-25.02%193.58M
143.47%462.96M
-99.50%962K
90,033.33%202.8M
149.59%1.03M
18,119.62%258.17M
Net common stock issuance
-14.24%397.3M
--0
-76.61%47.52M
--151.87M
-23.91%197.91M
144.47%463.28M
-100.00%1K
--203.18M
--0
--260.1M
Proceeds from stock option exercised by employees
151.44%6.22M
178.03%3.19M
--713K
47.21%1.95M
--364K
-24.99%2.47M
6.90%1.15M
--0
127.84%1.33M
--0
Net other financing activities
-360.04%-12.86M
-373.12%-880K
-1,556.20%-6.28M
-232.23%-1M
-143.70%-4.7M
-5.51%-2.8M
---186K
---379K
---301K
---1.93M
Cash from discontinued financing activities
Financing cash flow
-15.62%390.66M
140.02%2.31M
-79.31%41.95M
14,809.76%152.83M
-25.02%193.58M
143.47%462.96M
-99.50%962K
90,033.33%202.8M
149.59%1.03M
18,119.62%258.17M
Net cash flow
Beginning cash position
-23.87%181.32M
-48.96%170.54M
-20.69%235.11M
-74.43%140.62M
-23.87%181.32M
182.47%238.16M
167.76%334.15M
158.89%296.44M
458.61%549.91M
182.47%238.16M
Current changes in cash
-8.54%-58.72M
69.64%-47.31M
-265.78%-65.82M
137.89%94.62M
-112.90%-40.21M
-135.17%-54.1M
-237.48%-155.85M
285.80%39.7M
-1,654.74%-249.71M
2,106.16%311.75M
Effect of exchange rate changes
80.26%-541K
-138.99%-1.18M
162.87%1.25M
96.68%-125K
---491K
---2.74M
--3.02M
---1.99M
---3.77M
--0
End cash Position
-32.69%122.05M
-32.69%122.05M
-48.96%170.54M
-20.69%235.11M
-74.43%140.62M
-23.87%181.32M
-23.87%181.32M
167.76%334.15M
158.89%296.44M
458.61%549.91M
Free cash flow
5.22%-364.05M
11.47%-77.46M
30.12%-61.26M
4.45%-98.87M
-19.88%-126.45M
-22.65%-384.11M
-8.43%-87.5M
-34.79%-87.66M
-25.86%-103.47M
-23.74%-105.48M
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
Unqualified Opinion
--
--
--
--
Unqualified Opinion
--
--
--
--
(FY)Dec 31, 2024(Q4)Dec 31, 2024(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities 2.44%-352.98M12.71%-73.3M29.86%-58.97M-4.77%-98.43M-22.51%-122.28M-23.59%-361.82M-8.11%-83.97M-32.10%-84.08M-21.02%-93.95M-35.25%-99.82M
Net income from continuing operations 16.18%-372.18M32.50%-78.56M26.56%-83.54M8.85%-97.1M-5.22%-112.98M-12.16%-444.04M-10.50%-116.38M-14.20%-113.76M-7.23%-106.53M-17.21%-107.37M
Operating gains losses -8,304.29%-5.74M-5,149.06%-5.56M-126.05%-93K--10K---96K--70K---106K--357K--------
Depreciation and amortization 31.63%43.61M20.31%11.69M12.89%11.15M38.55%10.86M73.90%9.91M56.74%33.13M70.21%9.71M89.83%9.88M49.41%7.84M14.44%5.7M
Deferred tax 18.71%-2.83M188.63%1.56M-22.37%-1.52M-205.66%-1.46M---1.41M---3.48M---1.76M---1.24M---477K--0
Change In working capital -1,779.40%-122.56M-419.47%-37.98M-326.10%-13.32M-237.50%-38.71M-153.71%-32.55M-125.48%-6.52M295.87%11.89M-45.73%5.89M-77.66%-11.47M-24.64%-12.83M
-Change in receivables -46,335.57%-69.19M-9,008.72%-13.57M-73,324.24%-24.16M-94,960.61%-31.37M---83K---149K---149K--33K---33K--0
-Change in inventory -294.51%-39.92M-1,357.20%-13.45M-3,171.47%-10.87M7.23%-8.86M---6.74M---10.12M---923K--354K---9.55M--0
-Change in prepaid assets 79.00%-2.11M-3.30%-5.32M-214.92%-2.47M92.55%-211K239.16%5.89M-372.39%-10.06M-280.89%-5.15M192.92%2.15M-368.88%-2.83M-13.89%-4.23M
-Change in payables and accrued expense -97.00%737K-109.54%-1.99M340.18%27.14M21.44%4.42M-378.19%-28.83M1,984.92%24.6M744.95%20.83M-55.02%6.17M147.11%3.64M17.05%-6.03M
-Change in other current liabilities -11.86%-12.07M-34.23%-3.65M-4.69%-2.95M0.11%-2.69M-8.56%-2.79M-455.82%-10.79M-17.85%-2.72M-424.81%-2.81M-1,369.81%-2.69M-472.32%-2.57M
Cash from discontinued investing activities
Operating cash flow 2.44%-352.98M12.71%-73.3M29.86%-58.97M-4.77%-98.43M-22.51%-122.28M-23.59%-361.82M-8.11%-83.97M-32.10%-84.08M-21.02%-93.95M-35.25%-99.82M
Investing cash flow
Cash flow from continuing investing activities 37.90%-96.41M132.50%23.68M38.24%-48.8M125.65%40.22M-172.69%-111.51M-160.53%-155.24M-15,901.52%-72.85M-207.19%-79.01M-263.72%-156.78M77.30%153.4M
Net PPE purchase and sale 50.34%-11.07M-18.11%-4.17M36.04%-2.29M95.36%-442K26.36%-4.17M-9.13%-22.29M-16.78%-3.53M-157.89%-3.58M-108.04%-9.52M50.49%-5.66M
Net business purchase and sale 75.28%-52.57M--0--0--0---52.57M---212.63M--253K---3.38M---209.51M--0
Net investment purchase and sale -141.13%-32.77M140.03%27.85M35.45%-46.51M-34.68%40.66M-134.43%-54.76M-71.22%79.68M-2,097.39%-69.57M-195.95%-72.06M-37.96%62.25M62.38%159.06M
Cash from discontinued investing activities
Investing cash flow 37.90%-96.41M132.50%23.68M38.24%-48.8M125.65%40.22M-172.69%-111.51M-160.53%-155.24M-15,901.52%-72.85M-207.19%-79.01M-263.72%-156.78M77.30%153.4M
Financing cash flow
Cash flow from continuing financing activities -15.62%390.66M140.02%2.31M-79.31%41.95M14,809.76%152.83M-25.02%193.58M143.47%462.96M-99.50%962K90,033.33%202.8M149.59%1.03M18,119.62%258.17M
Net common stock issuance -14.24%397.3M--0-76.61%47.52M--151.87M-23.91%197.91M144.47%463.28M-100.00%1K--203.18M--0--260.1M
Proceeds from stock option exercised by employees 151.44%6.22M178.03%3.19M--713K47.21%1.95M--364K-24.99%2.47M6.90%1.15M--0127.84%1.33M--0
Net other financing activities -360.04%-12.86M-373.12%-880K-1,556.20%-6.28M-232.23%-1M-143.70%-4.7M-5.51%-2.8M---186K---379K---301K---1.93M
Cash from discontinued financing activities
Financing cash flow -15.62%390.66M140.02%2.31M-79.31%41.95M14,809.76%152.83M-25.02%193.58M143.47%462.96M-99.50%962K90,033.33%202.8M149.59%1.03M18,119.62%258.17M
Net cash flow
Beginning cash position -23.87%181.32M-48.96%170.54M-20.69%235.11M-74.43%140.62M-23.87%181.32M182.47%238.16M167.76%334.15M158.89%296.44M458.61%549.91M182.47%238.16M
Current changes in cash -8.54%-58.72M69.64%-47.31M-265.78%-65.82M137.89%94.62M-112.90%-40.21M-135.17%-54.1M-237.48%-155.85M285.80%39.7M-1,654.74%-249.71M2,106.16%311.75M
Effect of exchange rate changes 80.26%-541K-138.99%-1.18M162.87%1.25M96.68%-125K---491K---2.74M--3.02M---1.99M---3.77M--0
End cash Position -32.69%122.05M-32.69%122.05M-48.96%170.54M-20.69%235.11M-74.43%140.62M-23.87%181.32M-23.87%181.32M167.76%334.15M158.89%296.44M458.61%549.91M
Free cash flow 5.22%-364.05M11.47%-77.46M30.12%-61.26M4.45%-98.87M-19.88%-126.45M-22.65%-384.11M-8.43%-87.5M-34.79%-87.66M-25.86%-103.47M-23.74%-105.48M
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions Unqualified Opinion--------Unqualified Opinion--------

Market Insights

Best Growth Stocks Best Growth Stocks

Spot stocks with huge growth potential and solid financial standing. Spot stocks with huge growth potential and solid financial standing.

No. Symbol Price
AIRPORTS OF THAILAND PUBLIC CO UNSP ADR EACH REP 10 ORD SHS
AIPUY
13.460
New Fortress Energy
NFE
11.170
Cars.com
CARS
11.640
4
Halozyme Therapeutics
HALO
65.160
5
Collegium Pharmaceutical
COLL
30.050
Log In for the Full List
Unlock Now
Investment Course
Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context, Show More
MicroStrategy Q4 2024 earnings conference call
Monetary Policy: Navigating the Fed's Rate Cut Cycle
Changing Fed policy is altering the market math for investors.